{"id":904249,"date":"2025-11-03T10:40:11","date_gmt":"2025-11-03T15:40:11","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-cryoablation-system-combined-with-radiation-therapy-successfully-treats-non-small-cell-lung-cancer-nsclc-with-92-disease-specific-5-year-survival\/"},"modified":"2025-11-03T10:40:11","modified_gmt":"2025-11-03T15:40:11","slug":"icecures-cryoablation-system-combined-with-radiation-therapy-successfully-treats-non-small-cell-lung-cancer-nsclc-with-92-disease-specific-5-year-survival","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/icecures-cryoablation-system-combined-with-radiation-therapy-successfully-treats-non-small-cell-lung-cancer-nsclc-with-92-disease-specific-5-year-survival\/","title":{"rendered":"IceCure’s Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n 5-year overall survival (OS) rate for stereotactic body radiation therapy (SBRT) followed by cryoablation was 74%, compared to published studies reporting 5-year OS of 41% – 52% with SBRT alone\u00a0<\/i>\n <\/p>\n

\n SBRT followed by cryoablation produced 5-year OS outcomes similar to surgery, which has a 5-year OS of 67% – 82% according to published studies<\/i>\n <\/p>\n

\n Lung cancer is the most frequently diagnosed cancer worldwide with an incidence of 2.5 million cases and remains the leading cause of cancer-related death<\/i>\n <\/p>\n

\n
\n CAESAREA, Israel<\/span>
\n <\/span>, Nov. 3, 2025<\/span><\/span> \/PRNewswire\/ — IceCure Medical Ltd.<\/a> (NASDAQ: ICCM) (“IceCure”, “IceCure Medical” or the “Company”), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced the publication of an independent study using IceCure’s Cryoablation System titled “Long-term outcomes of combination therapy with stereotactic body radiation therapy plus cryoablation using liquid nitrogen for stage I non-small cell lung cancer with tumors \u22652 cm” in the peer-reviewed journal PLOS One<\/a><\/i>. The study was led by Dr. Hiroaki Nomori of the Department of Thoracic Surgery, Kashiwa Kousei General Hospital, Japan<\/span>, along with researchers from Tokyo University<\/span> Hospital, Kashiwa Kousei General Hospital, and Sonodakai Radiation Clinic, Tokyo<\/span>.<\/p>\n

\n

\n
\n \"(a)
\n <\/a>\n <\/p>\n<\/p><\/div>\n

“While radiation therapy is the standard of care for inoperable stage I NSCLC patients, using SBRT alone unfortunately results in far lower overall survival and lower local control than surgery in certain patients. This study, which focused on people with relatively larger tumors, indicative of later stage disease, provides very encouraging results confirming that combining SBRT with our cryoablation system offers inoperable patients longer life expectancy and may also provide a minimally invasive option to surgery for the broader population of stage I NSCLC patients,” stated IceCure’s Chief Executive Officer, Eyal Shamir<\/span>. “The results of this study may be highly impactful in our major markets including the U.S. and Europe<\/span>.”<\/p>\n

The objective of the independent retrospective observational study was to evaluate the effectiveness of combining SBRT with cryoablation for treating stage I NSCLC tumors \u22652 cm, given the limitations of local control and survival rates with SBRT monotherapy. 64 patients with tumors of mean diameter of 2.7 \u00b1 0.5 cm and a range of 2.0\u20134.0 cm were treated with SBRT, followed by cryoablation. The median follow-up duration was 74 months, with a range of 3-111 months.<\/p>\n

\n Results include the following: <\/b>\n <\/p>\n